Want to join the conversation?
$MRK said that the US Food and Drug Administration has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), its anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma. The company stated that this is the fourth Breakthrough Therapy Designation granted for KEYTRUDA.
$TWTR rolled out an iOS update Dec. 8 night that killed its famous "@" symbol. This lead to confusion among the iOS users when they tried it to reply to tweets.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.